文献速递骨质疏松与代谢性骨病

结节病患者的全身性糖皮质激素使用与大骨质疏松性骨折风险

Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis.
PubMed 文献 · Osteoporos Int · 2017-06-21

基于丹麦国家医院出院登记库1995年1月至2011年12月的病例对照研究,纳入376858例大骨质疏松性骨折患者及等量对照。结节病患者当前使用糖皮质激素与大骨质疏松性骨折风险升高相关(校正OR 1.74;95%CI 1.17-2.58),停药后回落至基线水平;无结节病者风险相当(校正OR 1.36;95%CI 1.32-1.40)。结节病本身与骨折风险升高无关。

要点

  • 结节病患者当前使用糖皮质激素与大骨质疏松性骨折风险升高相关,停药后降至基线水平。
  • 无结节病人群当前使用糖皮质激素的骨折风险与结节病患者相当,组间无差异。
  • 结节病本身与骨折风险升高无关,未用糖皮质激素者可能仅在启动激素治疗时需风险评估。

核心结论

  • 无论有无结节病,当前暴露于糖皮质激素均与大骨质疏松性骨折风险升高相关,组间无差异。
  • 结节病本身与骨折风险升高无关;未接受糖皮质激素治疗的结节病患者可能仅在启动激素治疗时需风险评估。

研究设计与样本

  • 病例对照研究,使用丹麦国家医院出院登记库1995年1月至2011年12月数据。
  • 采用条件logistic回归模型计算有无结节病者大骨质疏松性骨折的校正比值比(OR),按平均日剂量和累积剂量分层。
  • 共识别376858例大骨质疏松性骨折患者及等量无此事件对照(平均年龄64.2±19.5岁,女性占69%)。

主要发现

  • 结节病患者(n=124)当前使用糖皮质激素与大骨质疏松性骨折风险升高相关(校正OR 1.74;95%CI 1.17-2.58),停药后回落至基线水平。
  • 无结节病者当前使用糖皮质激素的风险相当(校正OR 1.36;95%CI 1.32-1.40)。
  • 结节病患者累积剂量1.0-4.9 g泼尼松龙当量与骨折风险升高相关(校正OR 2.75;95%CI 1.06-7.14)。
  • 结节病患者累积剂量>10 g泼尼松龙当量与骨折风险升高相关(校正OR 2.22;95%CI 1.17-4.22)。
  • 结节病患者累积剂量<1.0 g和5.0-9.9 g与大骨质疏松性骨折风险无关。

关键数值与推荐

  • 结节病患者当前使用糖皮质激素:校正OR 1.74(95%CI 1.17-2.58)。
  • 无结节病者当前使用糖皮质激素:校正OR 1.36(95%CI 1.32-1.40)。
  • 结节病患者累积剂量1.0-4.9 g泼尼松龙当量:校正OR 2.75(95%CI 1.06-7.14)。
  • 结节病患者累积剂量>10 g泼尼松龙当量:校正OR 2.22(95%CI 1.17-4.22)。

临床怎么用

  • 作者认为,结节病本身即未接受糖皮质激素治疗时并非骨折危险因素,此类患者可能仅在启动糖皮质激素治疗时需进行风险评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This study revealed the risk of major osteoporotic fracture in patients with sarcoidosis exposed to glucocorticoids. Current use of glucocorticoids was associated with a risk of fracture, with no difference between patients with and without sarcoidosis. Sarcoidosis per se was not associated with an increased fracture risk. INTRODUCTION: Sarcoidosis is a multi-organ, chronic inflammatory, granulomatous disorder that most frequently affects the lungs, lymph nodes, skin, eyes, and liver, but may occur in any organ, including the bones. While oral glucocorticoids (GCs) are commonly used as initial treatment, little is known about the risk of major osteoporotic fractures in patients with sarcoidosis exposed to GCs. METHODS: A case-control study was conducted using the Danish National Hospital Discharge Registry (NHDR) between January 1995 and December 2011. Conditional logistics regression models were used to derive adjusted odds ratios (OR) of major osteoporotic fractures in subjects with and without sarcoidosis stratified by average daily and cumulative dose exposures. RESULTS: A total of 376,858 subjects with a major osteoporotic fracture and the same number of subjects without this event were identified (mean age 64.2 ± 19.5 years, 69% female). In patients with sarcoidosis (n = 124), current use of GC was associated with an increased risk of major osteoporotic fracture (adjusted (adj.) OR 1.74; 95% CI 1.17-2.58), which dropped to baseline levels after discontinuation. In subjects without sarcoidosis, this risk was comparable (adj. OR 1.36; 95% CI 1.32-1.40). In sarcoidosis patients, cumulative dose 1.0-4.9 g and >10 g prednisolone equivalents were associated with increased risk of major osteoporotic fracture (adj. OR 2.75; 95% CI 1.06-7.14 and 2.22; 95% CI 1.17-4.22, respectively), whereas a cumulative dose of <1.0 g and 5.0-9.9 g was not associated with major osteoporotic fracture risk. CONCLUSION: Both in subjects with and without sarcoidosis, current expose to GC is associated with increased risk of major osteoporotic fractures, with no between-group difference. Sarcoidosis per se was not associated with increased fracture risk. Having sarcoidosis per se, i.e., if not treated with GC, is not a risk factor for fracture, and such patients may only need risk assessment when they commence GC therapy.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Oshagbemi OA, Driessen JHM, Pieffers A, et al. Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis. Osteoporos Int. 2017. PMID: 28638981. doi:10.1007/s00198-017-4115-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。